Qualigen Therapeutics Inc

NASDAQ:QLGNUnited States

Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.

Contact Information

Headquarters

1880 Century Park E Ste 1000LOS ANGELES, CA, United States 90067-1623

Phone

310-203-1000

Fax

310-919-1600

Executives

Chairman of the Board, Chief Executive Officer

Michael Poirier

President, Chief Strategy and Operating Officer, Director

Amy Broidrick

Chief Financial Officer, Vice President - Finance

Christopher Lotz

Senior Vice President, Chief Medical Officer

Tariq Arshad

Chief Scientific Officer, Vice President - Research and Development

Wajdi Abdul-Ahad